Affimed: Q1 Earnings Insights

Shares of Affimed AFMD decreased 3.0% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 500.00% year over year to ($0.12), which beat the estimate of ($0.14).

Revenue of $5,664,000 decreased by 55.45% from the same period last year, which missed the estimate of $5,930,000.

Looking Ahead

Affimed hasn't issued any earnings guidance for the time being.

Affimed hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Jun 23, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/n5vo3v39

Recent Stock Performance

52-week high: $3.96

Company's 52-week low was at $1.42

Price action over last quarter: Up 94.55%

Company Description

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.